BACKGROUND: Concurrent chemotherapy and @entity1514 ( @entity1514 ) is recommended for @entity151 ( @entity151 ). Twice daily @entity1514 is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about @entity137 . A schedule of three-week hypofractionated @entity1514 is a commonly used alternative. This is the first randomized trial comparing twice daily and hypofractionated @entity1514 in @entity151 . MATERIAL AND METHODS: @entity1 received four courses of @entity900 / @entity2879 (PE) and were randomized to @entity1514 of 42 Gy in 15 fractions (once daily, @entity5771 ) or 45 Gy in 30 fractions (twice daily, BID) between the second and third PE course. Good responders received prophylactic cranial irradiation of 30 Gy in 15 fractions. RESULTS: 157 @entity1 were enrolled between May 2005 and January 2011 ( @entity5771 : n   =   84, BID: n   =   73). Median age was 63 years, 52% were @entity1 , 84% had performance status 0-1, 72% had @entity5 and 11% non-malignant @entity1143 . The treatment arms were well balanced. The response rates were similar ( @entity5771 : 92%, BID: 88%; p   =   0.41), but more BID @entity1 achieved a complete response ( @entity5771 : 13%, BID: 33%; p   =   0.003). There was no difference in one-year progression-free survival (PFS) ( @entity5771 : 45%, BID: 49%; p   =   0.61) or median PFS ( @entity5771 : 10.2 months, BID: 11.4 months; p   =   0.93). The median overall survival in the BID arm was 6.3 months longer ( @entity5771 : 18.8 months, BID: 25.1 months; p   =   0.61). There were no differences in grade 3-4 @entity2910 ( @entity5771 : 31%, BID: 33%, p   =   0.80) or @entity55 ( @entity5771 : 2%, BID: 3%, p   =   1.0). @entity1 on the BID arm reported slightly more @entity1282 at the end of the @entity1514 . CONCLUSION: There was no difference in severe @entity137 between the two @entity1514 schedules. The twice daily schedule resulted in significantly more complete responses and a numerically longer median overall survival, but no firm conclusions about efficacy could be drawn from this phase II trial.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated @entity1514 in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III disease'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['thoracic radiotherapy', 'TRT'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia'] @entity5771 :: ('OMIM:165800', 'Disease') :: ['OD'] @entity151 :: ('MESH:D055752', 'Disease') :: ['limited disease small cell lung cancer', 'LD SCLC']
@entity151 :: (MESH:D055752,Disease) :: ['limited disease small cell lung cancer']
